Nls Pharmaceutics Ltd (NLSP) Stock Price, Quote & News

Company Profile

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience for the treatment of narcolepsy; and N...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 44 512 21 50

Fax: 41 44 512 21 51

Website: nlspharma.com

Address:

The Circle 6, Zurich, Switzerland

Diverter Jun. 16 at 12:46 PM

$NLSP

0 · Reply

Navid62 Jun. 16 at 12:44 PM

$NLSP

0 · Reply

BannedForBeingABrokeDude Jun. 16 at 12:35 PM

$NLSP LETS PUSH THIS MOTHER FUCKER!!!!!

0 · Reply

Navid62 Jun. 16 at 12:24 PM

$NLSP

0 · Reply

JL_TradeZ Jun. 16 at 11:33 AM

$NLSP is setting up with real biotech momentum. They locked in a $2.5M financing at premiums and announced a merger with Kadimastem to form NewcelX, focused on ALS, diabetes, and neurodegeneration. All debt was wiped, and filings confirm a clean balance sheet. Now coiling just under 2.34 with early volume building. Float is thin and this has room if it clears. Watching for a move toward 2.55 then 2.80+ https://www.kadimastem.com/post/kadimastem-and-nls-pharmaceutics-announces-up-to-3-million-equity-financing-and-25-million-equity?utm_source

1 · Reply

frankyboyz Jun. 16 at 11:27 AM

PR $NLSP NLS Pharmaceutics (NASDAQ: NLSP) has announced significant progress in Q1 2025, including successful financing events totaling $2.5M at premium share prices and a $25M equity facility commitment. The company completed two equity financings at $3.10 and $1.65 per share, representing 48% and 10% premiums respectively. A transformative merger with Kadimastem (TASE: KDST) is expected to close in early Q3 2025, creating NewcelX, a combined entity focusing on neurodegenerative diseases and diabetes treatments. The company reported positive preclinical data for AEX-2 and encouraging results for Mazindol ER in fentanyl-related studies. Post-merger plans include initiating a Phase IIa trial for AstroRx in ALS treatment, Phase I study for IsletRx in Type I diabetes, and advancing preclinical development of AEX-2/AEX-41 for narcolepsy and neurodegeneration. The company has converted all outstanding liabilities to equity, achieving a debt-free status.

0 · Reply

beppels Jun. 16 at 11:22 AM

$NLSP great news, ceo letter to shareholders! https://www.stocktitan.net/news/NLSP/nls-pharmaceutics-ceo-issues-letter-to-tic3nty1pm6j.html

0 · Reply

AlwaysBullish99 Jun. 16 at 12:58 AM

$NLSP Under the radar with a $70,000,000 dollar merger pending

1 · Reply

BioNerd77 Jun. 16 at 12:15 AM

$NLSP and $SSY merger plays to keep watch on!

0 · Reply

Takeiteasy30 Jun. 13 at 5:53 PM

$TTNP Still quiet as hell. Mergers news 2 weeks ago. Tiny float - got a chance to shoot up out of nothing. Only lottery ticket here. Played $NLSP and $EYEN before with profit lets see what this brings

0 · Reply

NLS Pharmaceutics CEO Issues Letter to Shareholders

May 21, 2025, 7:30 AM EDT - 26 days ago

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

Apr 15, 2025, 9:00 AM EDT - 2 months ago

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

Mar 31, 2025, 9:10 AM EDT - 2 months ago

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

Mar 10, 2025, 7:00 AM EDT - 3 months ago

NLS Pharmaceutics CEO Issues Letter to Shareholders

Feb 27, 2025, 7:00 AM EST - 3 months ago

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Feb 25, 2025, 9:05 AM EST - 3 months ago

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Feb 10, 2025, 7:30 AM EST - 4 months ago

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Jan 31, 2025, 7:30 AM EST - 4 months ago

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

Jan 30, 2025, 7:30 AM EST - 4 months ago

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

Jan 28, 2025, 7:30 AM EST - 4 months ago

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Jan 16, 2025, 9:32 AM EST - 5 months ago

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

Jan 8, 2025, 7:42 AM EST - 5 months ago

NLS Pharmaceutics Ltd. and Kadimastem Ltd.

Dec 19, 2024, 7:30 AM EST - 6 months ago

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

Dec 4, 2024, 1:15 PM EST - 6 months ago

NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

Dec 3, 2024, 7:40 AM EST - 6 months ago

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

Nov 18, 2024, 7:30 AM EST - 7 months ago

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

Nov 4, 2024, 7:00 AM EST - 8 months ago

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

Oct 28, 2024, 7:00 AM EDT - 8 months ago

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

Oct 21, 2024, 7:00 AM EDT - 8 months ago

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

Oct 15, 2024, 7:00 AM EDT - 8 months ago

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules

Sep 25, 2024, 8:00 AM EDT - 9 months ago

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split

Jul 29, 2024, 12:03 PM EDT - 11 months ago

Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump

Jul 29, 2024, 7:00 AM EDT - 11 months ago

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

Jun 28, 2024, 9:00 AM EDT - 1 year ago

NLS Pharmaceutics Announces Registered Direct Offering

Jun 27, 2024, 8:00 AM EDT - 1 year ago

NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments

Jun 25, 2024, 8:30 AM EDT - 1 year ago

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements

Jun 11, 2024, 8:30 AM EDT - 1 year ago

NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

Apr 19, 2024, 5:00 PM EDT - 1 year ago

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

Mar 22, 2024, 4:30 PM EDT - 1 year ago

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

Mar 20, 2024, 1:40 PM EDT - 1 year ago

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

Mar 20, 2024, 7:30 AM EDT - 1 year ago

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

Mar 14, 2024, 8:00 AM EDT - 1 year ago

NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance

Feb 23, 2024, 7:30 AM EST - 1 year ago

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

Jan 12, 2024, 4:30 PM EST - 1 year ago

Notice of Deficiency with Nasdaq Continued Listing Requirements

Dec 1, 2023, 7:30 AM EST - 1 year ago

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

Nov 28, 2023, 7:30 AM EST - 1 year ago

NLS Pharmaceutics Announces Election of Additional Board Members

Nov 27, 2023, 8:30 AM EST - 1 year ago

NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia

Nov 16, 2023, 8:00 AM EST - 1 year ago

NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan

Oct 25, 2023, 4:30 PM EDT - 1 year ago

NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Oct 19, 2023, 5:00 PM EDT - 1 year ago

NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions

Oct 12, 2023, 9:40 AM EDT - 1 year ago

NLS Pharmaceutics Announces Company Update on Strategic Partnerships

Jul 3, 2023, 8:53 AM EDT - 2 years ago

NLS Pharmaceutics shares rise as narcolepsy treatment moves to phase 3 studies

Jul 3, 2023, 7:00 AM EDT - 2 years ago

NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol

Jun 30, 2023, 4:05 PM EDT - 2 years ago

NLS Pharmaceutics Releases the Results from its Annual General Meeting

Jun 30, 2023, 8:00 AM EDT - 2 years ago

NLS Pharmaceutics Company Update and Webcast Today Postponed

Jun 19, 2023, 7:30 AM EDT - 2 years ago

CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Jun 19, 2023, 7:10 AM EDT - 2 years ago

NLS Pharmaceutics Announces Company Update Webcast

Jun 15, 2023, 8:30 AM EDT - 2 years ago

NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Diverter Jun. 16 at 12:46 PM

$NLSP

0 · Reply

Navid62 Jun. 16 at 12:44 PM

$NLSP

0 · Reply

BannedForBeingABrokeDude Jun. 16 at 12:35 PM

$NLSP LETS PUSH THIS MOTHER FUCKER!!!!!

0 · Reply

Navid62 Jun. 16 at 12:24 PM

$NLSP

0 · Reply

JL_TradeZ Jun. 16 at 11:33 AM

1 · Reply

frankyboyz Jun. 16 at 11:27 AM

0 · Reply

beppels Jun. 16 at 11:22 AM

$NLSP great news, ceo letter to shareholders! https://www.stocktitan.net/news/NLSP/nls-pharmaceutics-ceo-issues-letter-to-tic3nty1pm6j.html

0 · Reply

AlwaysBullish99 Jun. 16 at 12:58 AM

$NLSP Under the radar with a $70,000,000 dollar merger pending

1 · Reply

BioNerd77 Jun. 16 at 12:15 AM

$NLSP and $SSY merger plays to keep watch on!

0 · Reply

Takeiteasy30 Jun. 13 at 5:53 PM

0 · Reply

keo12010 Jun. 13 at 1:37 AM

$BNZI $NLSP $SBET $SDOT $XTIA

0 · Reply

shahwinner Jun. 12 at 7:12 PM

$NLSP what is happening with this stock?

0 · Reply

poptime717 Jun. 12 at 3:28 PM

$NLSP whats going on here

0 · Reply

jm77 Jun. 11 at 4:06 PM

$NLSP patience will be rewarded

0 · Reply

StockfatherOG Jun. 11 at 12:46 PM

$NLSP shorts piled in yesterday which is good. The more shorts that get trapped going into the merger, the bigger the squeeze.

0 · Reply

Pillemann1 Jun. 11 at 10:49 AM

$NLSP stay patient

0 · Reply

JL_TradeZ Jun. 11 at 12:11 AM

Everyone’s chasing green candles — I’m focused on setups before they move. $KWM, $LVWR, $ABP, $NCNA and $NLSP weren’t hot when I posted them. No hype. Just clean setups + high-conviction catalysts. Look at them now. +96%, +79%, +35%… and that’s just this week. I’m not here to flex. I’m here to keep showing what happens when you stop reacting late and start reading the tape + filings ahead of time. The next one’s already on the radar. Stay close.

2 · Reply